|Trade names||Andractim, others|
|Other names||Stanolone; Dihydrotestosterone; DHT; 5α-Dihydrotestosterone; 5α-DHT|
|Transdermal (gel), in the cheek, under the tongue, intramuscular injection (as esters)|
|Drug class||Androgen; Anabolic steroid|
|Bioavailability||Oral: Very low|
IM injection: 100%
|Elimination half-life||Transdermal: 2.8 hours|
|Chemical and physical data|
|Molar mass||290.442 g/mol g·mol−1|
|3D model (JSmol)|
Androstanolone, or stanolone, also known as dihydrotestosterone (DHT) and sold under the brand name Andractim among others, is an androgen and anabolic steroid (AAS) medication and hormone which is used mainly in the treatment of low testosterone levels in men. It is also used to treat breast development and small penis in males. It is typically given as a gel for application to the skin, but can also be used as an ester by injection into muscle.
Side effects of androstanolone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. The medication is a naturally occurring androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and DHT. It has strong androgenic effects and weak muscle-building effects, as well as no estrogenic effects.
Androstanolone was discovered in 1935 and was introduced for medical use in 1953. It is used mostly in France and Belgium. The drug has been used by weightlifters to increase performance due to its powerful androgenic properties. The medication is a controlled substance in many countries and so non-medical use is generally illicit.
- 1 Medical uses
- 2 Side effects
- 3 Pharmacology
- 4 Chemistry
- 5 History
- 6 Society and culture
- 7 Research
- 8 References
- 9 External links
Androstanolone is available in pharmaceutical formulations for medical use as an androgen. It is used mainly as a form of androgen replacement therapy in the treatment of male hypogonadism and is specifically approved for this indication in certain countries. However, it is no longer recommended for this purpose due to biological differences from testosterone such as lack of estrogenic effects and partial androgenic effects. Topical androstanolone is useful in the treatment of gynecomastia. Similarly, androstanolone enanthate via intramuscular injection has been found to be effective in the treatment persistent pubertal gynecomastia. The medication has also been used as a topical gel to treat small penis in pre- and peripubertal boys with mild or partial androgen insensitivity syndrome.
Androstanolone was found to be effective in the treatment of advanced breast cancer in women in the 1950s, although it was used in very high doses and caused severe virilization. It was used as a microcrystalline aqueous suspension by intramuscular injection. Shortly thereafter, drostanolone propionate (2α-methylandrostanolone propionate) was developed for this use instead of androstanolone due to its superior pharmacokinetics and was introduced for this indication in the United States and Europe in the early 1960s.
|Route||Medication||Major brand names||Form||Dosage|
|Oral||Testosteronea||–||Tablet||400–800 mg/day (in divided doses)|
|Testosterone undecanoate||Andriol, Jatenzo||Capsule||40–80 mg/2–4x day (with meals)|
|Methyltestosteroneb||Android, Metandren, Testred||Tablet||10–50 mg/day|
|Fluoxymesteroneb||Halotestin, Ora-Testryl, Ultandren||Tablet||5–20 mg/day|
|Buccal||Testosterone||Striant||Tablet||30 mg 2x/day|
|Methyltestosteroneb||Metandren, Oreton Methyl||Tablet||5–25 mg/day|
|Sublingual||Testosteronea||–||Tablet||5 mg 3x/day|
|Methyltestosteroneb||Metandren, Oreton Methyl||Tablet||10–30 mg/day|
|Intranasal||Testosterone||Natesto||Nasal spray||11 mg 3x/day|
|Transdermal||Testosterone||AndroGel, Testim, TestoGel||Gel||25–125 mg/day|
|Androderm, AndroPatch, TestoPatch||Non-scrotal patch||2.5–15 mg/day|
|Testoderm||Scrotal patch||4–6 mg/day|
|Axiron||Axillary solution||30–120 mg/day|
|Androstanolone (DHT)||Andractim||Gel||100–250 mg/day|
|Rectal||Testosterone||Rektandron, Testosteronb||Suppository||40 mg 2–3x/day|
|Injection (IM or SC)||Testosterone||Andronaq, Sterotate, Virosterone||Aqueous suspension||10–50 mg 2–3x/week|
|Testosterone propionateb||Testoviron||Oil solution||10–50 mg 2–3x/week|
|Testosterone enanthate||Delatestryl||Oil solution||50–250 mg 1x/1–4 weeks|
|Xyosted||Auto-injector||50–100 mg 1x/week|
|Testosterone cypionate||Depo-Testosterone||Oil solution||50–250 mg 1x/1–4 weeks|
|Testosterone isobutyrate||Agovirin Depot||Aqueous suspension||50–100 mg 1x/1–2 weeks|
|Mixed testosterone esters||Sustanon 100, Sustanon 250||Oil solution||50–250 mg 1x/2–4 weeks|
|Testosterone undecanoate||Aveed, Nebido||Oil solution||750–1,000 mg 1x/10–14 weeks|
|Testosterone buciclatea||–||Aqueous suspension||600–1,000 mg 1x/12–20 weeks|
|Implant||Testosterone||Testopel||Pellet||150–1,200 mg/3–6 months|
|Notes: Men produce about 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = Never marketed. b = No longer used and/or no longer marketed. Sources: See template.|
|Fluoxymesterone||Tablet||10–40 mg 3x/day|
|Calusterone||Tablet||40 mg 4x/day|
|Injection (IM or SC)||Testosterone propionate||Oil solution||50–100 mg 3x/week|
|Testosterone enanthate||Oil solution||200–400 mg 1x/2–4 weeks|
|Testosterone cypionate||Oil solution||200–400 mg 1x/2–4 weeks|
|Mixed testosterone esters||Oil solution||250 mg 1x/week|
|Methandriol||Aqueous suspension||100 mg 3x/week|
|Androstanolone (DHT)||Aqueous suspension||300 mg 3x/week|
|Drostanolone propionate||Oil solution||100 mg 3x/week|
|Nandrolone decanoate||Oil solution||50–100 mg 1x/1–3 weeks|
|Nandrolone phenylpropionate||Oil solution||50–100 mg/week|
|Note: Dosages are not necessarily equivalent. Sources: See template.|
The medication has also been marketed in the form of several androstanolone esters, including androstanolone benzoate (brand names Ermalone-Amp, Hermalone, Sarcosan), androstanolone enanthate (brand name Anaboleen Depot), androstanolone propionate (brand name Pesomax), and androstanolone valerate (brand name Apeton), which are provided as oil solutions for intramuscular injection at regular intervals.
Adverse effects of androstanolone are similar to those of other AAS and include androgenic side effects like oily skin, acne, seborrhea, increased facial/body hair growth, scalp hair loss, and increased aggressiveness and sex drive. In women, androstanolone can cause partially irreversible virilization, for instance voice deepening, hirsutism, clitoromegaly, breast atrophy, and muscle hypertrophy, as well as menstrual disturbances and reversible infertility. In men, the medication may also cause hypogonadism, testicular atrophy, and reversible infertility at sufficiently high dosages.
Androstanolone can have adverse effects on the cardiovascular system, especially with long-term administration of high dosages. AAS like androstanolone stimulate erythropoiesis (red blood cell production) and increase hematocrit levels and at high dosages can cause polycythemia (overproduction of red blood cells), which can greatly increase the risk of thrombic events such as embolism and stroke. Unlike many other AAS, androstanolone is not aromatized into estrogens and hence has no risk of estrogenic side effects like gynecomastia, fluid retention, or edema. In addition, as it is not a 17α-alkylated AAS and is administered parenterally, androstanolone has no risk of hepatotoxicity.
It has been theorized that androstanolone may have less risk of benign prostatic hyperplasia and prostate cancer than testosterone because it is not aromatized into estrogens. This is relevant because estrogens, in addition to estrogens, are thought to possibly be necessary for the manifestation of these diseases. In accordance, androstanolone has been found to not increase prostate gland size in men. Conversely, due to lack of aromatization into estrogens, androstanolone therapy for androgen replacement may result in decreased bone mineral density, incomplete effects in the brain, and undesirable changes in cholesterol levels.
|Notes: In rodents. Footnotes: a = Ratio of androgenic to anabolic activity. Sources: See template.|
Androstanolone is a potent agonist of the AR. It has an affinity (Kd) of 0.25 to 0.5 nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (Kd = 0.4 to 1.0 nM) and the dissociation rate of androstanolone from the AR is also about 5-fold slower than that of testosterone. The EC50 of androstanolone for activation of the AR is 0.13 nM, which is about 5-fold stronger than that of testosterone (EC50 = 0.66 nM). In bioassays, androstanolone has been found to be 2.5- to 10-fold more potent than testosterone.
Unlike testosterone and various other AAS, androstanolone cannot be aromatized, and for this reason, poses no risk of estrogenic side effects like gynecomastia at any dosage. In addition, androstanolone cannot be metabolized by 5α-reductase (as it is already 5α-reduced), and for this reason, is not potentiated in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland, thereby improving its ratio of anabolic to androgenic effects. However, androstanolone is nonetheless described as a very poor anabolic agent. This is attributed to its high affinity as a substrate for 3α-hydroxysteroid dehydrogenase (3α-HSD), which is highly expressed in skeletal muscle and inactivates androstanolone into 3α-androstanediol, a metabolite with very weak AR activity. Unlike androstanolone, testosterone is very resistant to metabolism by 3α-HSD, and so is not similarly inactivated in skeletal muscle. For the preceding reasons, androstanolone has been described as a "partial androgen".
The bioavailability of androstanolone differs considerably depending on its route of administration. Its oral bioavailability is very low, and androstanolone is considered to be ineffective by the oral route. The transdermal bioavailability of androstanolone is approximately 10%. Its bioavailability with intramuscular injection, on the other hand, is complete (100%).
Doses of topical androstanolone gel of 16, 32, and 64 mg have been found to produce total testosterone and DHT levels in the low, mid, and high normal adult male range, respectively.
The plasma protein binding of androstanolone is about 98.5 to 99.0%. It is bound 50 to 80% to sex hormone-binding globulin, 20 to 40% to albumin, and less than 0.5% to corticosteroid-binding globulin, with about 1.0 to 1.5% circulating freely or unbound.
The terminal half-life of androstanolone in the circulation (53 minutes) is longer than that of testosterone (34 minutes), and this may account for some of the difference in their potency. A study of transdermal androstanolone and testosterone therapy reported terminal half-lives of 2.83 hours and 1.29 hours, respectively.
Androstanolone, also known as 5α-androstan-17β-ol-3-one or as 5α-dihydrotestosterone (5α-DHT), is a naturally occurring androstane steroid with a ketone group at the C3 position and a hydroxyl group at the C17β position. It is the derivative of testosterone in which the double bond between the C4 and C5 positions has been reduced or hydrogenated.
Several C17β ester prodrugs of androstanolone, including androstanolone benzoate, androstanolone enanthate, androstanolone propionate, and androstanolone valerate, have been developed and introduced for medical use as AAS. Conversely, dihydrotestosterone acetate, dihydrotestosterone butyrate, and dihydrotestosterone formate have been developed but have not been marketed.
Androstanolone was first discovered and synthesized in 1935 by Adolf Butenandt and his colleagues. It was first introduced for medical use in 1953, under the brand name Neodrol in the United States, and was subsequently marketed in the United Kingdom and other European countries. Transdermal androstanolone gel has been available in France since 1982.
Society and culture
Brand names of androstanolone include Anaboleen, Anabolex, Anaprotin (UK), Andractim (formerly AndroGel-DHT) (FR, BE, LU), Androlone, Apeton, Gelovit (ES), Neodrol, Ophtovital (DE), Pesomax (IT), Stanaprol, and Stanolone, among others.
The availability of pharmaceutical androstanolone is limited; it is not available in the United States or Canada, but it is or has been available in certain European countries, including the United Kingdom, Germany, France, Spain, Italy, Belgium, and Luxembourg.
The available formulations of androstanolone include buccal or sublingual tablets (Anabolex, Stanolone), topical gels (Andractim, Gelovit, Ophtovital), and, as esters in oil, injectables like androstanolone propionate (Pesomax) and androstanolone valerate (Apeton). Androstanolone benzoate (Ermalone-Amp, Hermalone, Sarcosan) and androstanolone enanthate (Anaboleen Depot) are additional androstanolone esters that are available for medical use in some countries. Androstanolone esters act as prodrugs of androstanolone in the body and have a long-lasting depot effect when given via intramuscular injection.
In the early- to mid-2000s, transdermal or topical androstanolone was under development in the United States for the treatment of hypogonadism (as a form of androgen replacement therapy), male osteoporosis, and cachexia (in cancer patients) and in Australia for the treatment of benign prostatic hyperplasia (BPH). It reached phase II clinical trials for hypogonadism and BPH and phase III clinical studies for cachexia but development was ultimately never completed for these indications in these specific countries. Although androstanolone itself has not been approved for cachexia in any country, an orally active synthetic derivative of androstanolone, oxandrolone (2-oxa-17α-methylandrostanolone), is approved and used for this indication in the United States.
Topical androgens like androstanolone have been used and studied in the treatment of cellulite in women. Topical androstanolone on the abdomen has also been found to significantly decrease subcutaneous abdominal fat in women, and hence may be useful for improving body silhouette. However, men and hyperandrogenic women have higher amounts of abdominal fat than healthy women, and androgen therapy has been found to increase abdominal fat in postmenopausal women and transgender men.
- Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 8, 23–25, 353–359. ISBN 978-0-9828280-1-4.
- Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clinical Chemistry. 43 (11): 2091–8. PMID 9365393.
- von Deutsch DA, Abukhalaf IK, Lapu-Bula R (15 October 2003). "Anabolic Doping Agents". In Mozayani A, Raymon L (eds.). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 510–. doi:10.1007/978-1-61779-222-9_15. ISBN 978-1-59259-654-6.
- Hyde TE, Gengenbach MS (2007). Conservative Management of Sports Injuries. Jones & Bartlett Learning. pp. 1100–. ISBN 978-0-7637-3252-3.
- Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–21. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- Schnitzer R (1 January 1967). Experimental Chemotherapy. Elsevier Science. pp. 156–. ISBN 978-0-323-14611-1.
- Krüskemper HL (22 October 2013). Anabolic Steroids. Elsevier. pp. 12–. ISBN 978-1-4832-6504-9.
- Sittig M (2007). Pharmaceutical Manufacturing Encyclopedia. William Andrew Publishing. ISBN 978-0-8155-1526-5.
- Gooren LJ, Bunck MC (2004). "Androgen replacement therapy: present and future". Drugs. 64 (17): 1861–91. doi:10.2165/00003495-200464170-00002. PMID 15329035.
- "Public Disclosure". 2018-05-30.
- "Steroid Use by Chinese Hints at Systematic Doping".
- "Androstanolone - AdisInsight".
- Wang C, Swerdloff RS (October 1997). "Androgen replacement therapy". Annals of Medicine. 29 (5): 365–70. doi:10.3109/07853899708999363. PMID 9453281.
- Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA (June 2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. PMID 28472278.
- Swerdloff RS, Wang C (1998). "Dihydrotestosterone: A rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Baillière's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. ISSN 0950-351X.
- Wang C, Swerdloff RS (April 2002). "Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause?". The Journal of Clinical Endocrinology and Metabolism. 87 (4): 1462–6. doi:10.1210/jcem.87.4.8488. PMID 11932265.
- Byrne M, Nieschlag E (May 2003). "Testosterone replacement therapy in male hypogonadism". Journal of Endocrinological Investigation. 26 (5): 481–9. doi:10.1007/BF03345206. PMID 12906378.
- Rastrelli G, Guaraldi F, Reismann Y, Sforza A, Isidori AM, Maggi M, Corona G (July 2019). "Testosterone Replacement Therapy for Sexual Symptoms". Sexual Medicine Reviews. 7 (3): 464–475. doi:10.1007/978-981-13-1226-7_8. ISBN 978-981-13-1225-0. PMID 30803919.
- Agrawal S, Ganie MA, Nisar S (2017). "Gynaecomastia". Basics of Human Andrology. Singapore: Springer. pp. 451–458. doi:10.1007/978-981-10-3695-8_26. ISBN 978-981-10-3694-1.
- Eberle AJ, Sparrow JT, Keenan BS (July 1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". The Journal of Pediatrics. 109 (1): 144–9. doi:10.1016/S0022-3476(86)80596-0. PMID 3088241.
- Hohl A (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 91–. ISBN 978-3-319-46086-4.
- Becker D, Wain LM, Chong YH, Gosai SJ, Henderson NK, Milburn J, et al. (February 2016). "Topical dihydrotestosterone to treat micropenis secondary to partial androgen insensitivity syndrome (PAIS) before, during, and after puberty - a case series". Journal of Pediatric Endocrinology & Metabolism. 29 (2): 173–7. doi:10.1515/jpem-2015-0175. PMID 26352087.
- Gelhorn A, Holland J, Herrmann JB, Moss J, Smelin A (April 1954). "An evaluation of stanolone in treatment of advanced mammary cancer". Journal of the American Medical Association. 154 (15): 1274–7. PMID 13151839.
- Kennedy BJ (1955). "The effect of stanolone in the treatment of advanced breast cancer". Cancer. 8 (3): 488–97. doi:10.1002/1097-0142(1955)8:3<488::AID-CNCR2820080309>3.0.CO;2-Y. PMID 14379136.
- Segaloff A, Horwitt BN, Carabasi RA, Murison PJ, Schlosser JV (1955). "Hormonal therapy in cancer of the breast. VIII. The effect of dihydrotestosterone (androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–6. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. PMID 13231036.
- Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DJ (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
- Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.
- Segaloff A, Horwitt BN, Cakabasi RA, Murison PJ, Osser JV (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of dihydrotestosterone (Androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–86. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. ISSN 0008-543X.
- Blackburn CM, Childs DS (March 1959). "Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast". Proceedings of the Staff Meetings. Mayo Clinic. 34 (5): 113–26. PMID 13658242.
- Goldenberg IS, Hayes MA (1961). "Hormonal therapy of metastatic female breast carcinoma. II. 2alpha-Methyl dihydrotestosterone propionate". Cancer. 14 (4): 705–6. doi:10.1002/1097-0142(199007/08)14:4<705::AID-CNCR2820140405>3.0.CO;2-I. PMID 13706491.
- Thomas AN, Gordan GS, Lowe R (1962). "Antitumor efficacy of 2alpha-methyl dihydrotestosterone propionate in advanced breast cancer". Cancer. 15: 176–8. doi:10.1002/1097-0142(196201/02)15:1<176::AID-CNCR2820150124>3.0.CO;2-N. PMID 13920749.
- Sittig M (22 October 2013). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). William Andrew Publishing. pp. 1402–. ISBN 978-0-8155-1856-3.
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.
- Llewellyn W (2009). Anabolics. Molecular Nutrition Llc. pp. 19, 163. ISBN 978-0967930473.
- Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–21. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- Bagatell C, Bremner WJ (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 149, 325. ISBN 978-1-59259-388-0.
- Jones TH (2009). Advances in the Management of Testosterone Deficiency. Karger Medical and Scientific Publishers. pp. 40–. ISBN 978-3-8055-8622-1.
- Mozayani A, Raymon L (18 September 2011). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 656–. ISBN 978-1-61779-222-9.
- Grino PB, Griffin JE, Wilson JD (February 1990). "Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone". Endocrinology. 126 (2): 1165–72. doi:10.1210/endo-126-2-1165. PMID 2298157.
- Wilderer PA (1 September 2010). "Bioassays for Estrogenic and Androgenic Effects of Water Constituents". Treatise on Water Science, Four-Volume Set. Newnes. pp. 1805–. ISBN 978-0-444-53199-5.
- Malven PV (12 January 1993). Mammalian Neuroendocrinology. CRC Press. pp. 228–. ISBN 978-0-8493-8757-9.
- Nieschlag E, Behre HM, Nieschlag S (26 July 2012). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 61–. ISBN 978-1-107-01290-5.
- Diamanti-Kandarakis E (September 1999). "Current aspects of antiandrogen therapy in women". Current Pharmaceutical Design. 5 (9): 707–23. PMID 10495361.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1.
- Morton I, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
- Newsweek. Newsweek. 1953.
- New and Nonofficial Drugs. Lippincott. 1958.
- Lunenfeld B, Oettel M (2009). "Therapeutic potential of testosterone gels". Aging Health. 5 (2): 227–245. doi:10.2217/ahe.09.6. ISSN 1745-509X.
- List PH, Hörhammer L (12 March 2013). Chemikalien und Drogen: Teil B: R, S. Springer-Verlag. pp. 523–. ISBN 978-3-642-66377-2.
- "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 16 November 2016.
- "Drug Product Database - Health Canada". Health Canada. Retrieved 13 November 2016.
- Karch S (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN 978-1-4200-0346-8.
- "Androgen replacement therapy - AdisInsight".
- "Dihydrotestosterone-transdermal - AdisInsight".
- Nelms M, Sucher KP, Lacey K, Roth SL (16 June 2010). Nutrition Therapy and Pathophysiology. Cengage Learning. pp. 766–. ISBN 978-1-133-00809-5.
- Mantovani G (6 October 2007). Cachexia and Wasting: A Modern Approach. Springer Science & Business Media. pp. 673–. ISBN 978-88-470-0552-5.
- Gruber CJ, Wieser F, Gruber IM, Ferlitsch K, Gruber DM, Huber JC (December 2002). "Current concepts in aesthetic endocrinology". Gynecological Endocrinology. 16 (6): 431–41. doi:10.1080/gye.16.6.431.441. PMID 12626029.
- Sam S (February 2015). "Adiposity and metabolic dysfunction in polycystic ovary syndrome". Hormone Molecular Biology and Clinical Investigation. 21 (2): 107–16. doi:10.1515/hmbci-2015-0008. PMID 25781555.